Sign in Subscribe

dmmr

A collection of 120 issues

COMMIT Trial Evaluates Chemoimmunotherapy in dMMR Metastatic Colorectal Cancer

Skip to content The CRC Digest ◆ TRIAL DATA COMMIT Trial Evaluates Chemoimmunotherapy in dMMR Metastatic Colorectal Cancer A new analysis examines what the COMMIT trial can and cannot tell us about combining chemotherapy with immunotherapy in patients with deficient DNA mismatch repair (dMMR) metastatic colorectal cancer. (Journal of Clinical Oncology)

CRC Research Update — August 07, 2026

Today's colorectal cancer research highlights

National study examines surveillance colonoscopy in Lynch syndrome patients

Skip to content The CRC Digest ▪ SCREENING National study examines surveillance colonoscopy in Lynch syndrome patients A national study of 4,732 Lynch syndrome carriers in the English NHS assessed adherence to surveillance guidelines and aimed to determine the impact of colonoscopic surveillance on colorectal cancer incidence and mortality in

CRC Research Update — August 06, 2026

Today's colorectal cancer research highlights

Study Examines Universal Tumor Screening for Lynch Syndrome in Japan

Skip to content The CRC Digest ▪ SCREENING Study Examines Universal Tumor Screening for Lynch Syndrome in Japan A prospective study of 591 patients with stage II/III colorectal cancer in Japan aimed to clarify the clinical utility and cost-effectiveness of universal tumor screening using immunohistochemistry to identify Lynch syndrome, with

CRC Research Update — August 01, 2026

Today's colorectal cancer research highlights

Deficient mismatch repair is a distinct feature of early-onset CRC in Chinese cohort

Skip to content The CRC Digest Deficient mismatch repair is a distinct feature of early-onset CRC in Chinese cohort Among 4,159 colorectal cancer cases at West China Hospital, early-onset CRC (diagnosed before age 50) showed higher rates of deficient mismatch repair compared to late-onset disease. (Int J Cancer) This

Immunotherapy produces durable responses in dMMR/MSI-H metastatic CRC patients with poor performance status

Skip to content The CRC Digest ◆ TRIAL DATA Immunotherapy produces durable responses in dMMR/MSI-H metastatic CRC patients with poor performance status Research shows that patients with deficient mismatch repair or high microsatellite instability can benefit from immunotherapy even when they have poor performance status, a group often excluded from

CRC Research Update — July 30, 2026

Today's colorectal cancer research highlights

Phase III trial tests chemotherapy plus immunotherapy in MSI-H metastatic colorectal cancer

Skip to content The CRC Digest ◆ TRIAL DATA Phase III trial tests chemotherapy plus immunotherapy in MSI-H metastatic colorectal cancer The phase III COMMIT trial randomly assigned first-line mismatch repair-deficient metastatic colorectal cancer patients in a three-arm study comparing mFOLFOX6/bevacizumab/atezolizumab versus atezolizumab monotherapy, testing whether adding chemotherapy to